A substantial body of preclinical studies, including rodents and studies by Nestler, have confirmed the promising antidepressant effects of HDAC inhibitors, indicating their potential for treating treatment-resistant depression (Fuchikami et al., 2016). This evidence concerns the gene HDAC9 and major depressive disorder.